Arthneeti
Sigachi Indust.Q3 FY23

Sigachi Indust. Q3 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹37.9P/E: 64.5Market Cap: ₹1.4K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

N/A

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 2
  • The company plans significant growth through inorganic expansion by acquiring API (Active Pharmaceutical Ingredient) units.
  • Rs. 160 crores of the raised funds will be allocated towards acquisition or expansion of API units, indicating a strategic focus on capacity growth.
  • Rs. 78.8 crores are budgeted for developing the API unit in Kurnool, where land is already acquired.
  • Rs. 20 crores will be invested in upgrading the manufacturing facility at Hyderabad to enhance production capabilities.
  • Working capital requirements of Rs. 30 crores will support ongoing operations, sustaining revenue growth.
  • General corporate purposes are allocated Rs. 20-25 crores over two years to facilitate overall business growth.
  • The management is actively scouting acquisition opportunities to boost sales and volumes, with concrete plans to be shared once finalized.
  • The company is also considering a rights issue to existing shareholders to further support growth initiatives.

See what Sigachi Indust. management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes
  • The company is currently raising Rs. 313 crores through a proposed preferential issue by issuing convertible warrants to certain identified promoters and non-promoters.
  • A portion of Rs. 160 crores is allocated for acquisition or expansion of the API unit.
  • Rs. 78.8 crores will be spent on the API unit in Kurnool.
  • Rs. 20 crores are allocated for upgrading the manufacturing facility in Hyderabad.
  • Rs. 30 crores are allocated towards working capital, and Rs. 20-25 crores for general corporate purposes.
  • The company is actively looking for new acquisitions and inorganic growth opportunities.
  • There is a proposal for a rights issue, which will be discussed by the board for future fundraising.
  • No specific debt fundraising is mentioned in the transcript; focus is on equity through warrants and possible rights issue.

See what Sigachi Indust. management said on order book — free account, 30 seconds.

Capex plans

Yes
  • The company is raising Rs. 313 crores through a preferential issue for capital investment.
  • Rs. 160 crores will be spent toward acquisition or expansion of an API unit, reflecting the company’s goal for inorganic growth.
  • Rs. 78.8 crores is allocated for the development of the API unit in Kurnool; land for this has already been acquired.
  • Rs. 20 crores will be used to upgrade the manufacturing facility at Hyderabad.
  • An additional Rs. 30 crores is earmarked for working capital.
  • Rs. 20-25 crores is allocated for general corporate purposes, to be utilized over approximately two years.
  • The company is actively seeking new acquisition opportunities in the API segment and will update stakeholders once concrete plans are finalized.
  • There is also a proposal for a rights issue, which will be discussed by the board in due course.

Track Sigachi Indust. — get its next earnings analysis in your feed

Margin guidance

- The company is raising Rs. 313 crores through a preferential issue for growth purposes. - Rs. 160 crores will be spent on acquisition or expansion of the API unit, indicating focus on inorganic growth. - Rs. 78.8 crores allocated for the API unit development in Kurnool; land already acquired, showing concrete expansion plans. - Rs. 20 crores allocated for upgrading manufacturing facilities in Hyderabad to improve operating efficiency. - Working capital needs are Rs. 30 crores to support ongoing operations over the next two years. - Rs. 20-25 crores earmarked for general corporate purposes to maintain operational flexibility. - Management is actively looking for acquisition opportunities aligned with inorganic growth strategy, expected to enhance future earnings. - Rights issue proposal under consideration for further capital infusion and shareholder benefits. Overall, these strategic investments and expansions are expected to drive improved operating earnings, profits, and EPS growth in the medium term.

Order book

The provided transcript of Sigachi Industries Limited's 3rd EGM held on 04.02.2023 does not contain any information regarding the current or expected order book or pending orders. The discussions centered around: - Fundraising plans including preferential issue of Rs. 313 crores. - Utilization of funds towards acquisition/expansion of API units, manufacturing upgradation, working capital, and general corporate purposes. - Strategies for inorganic growth and possible future acquisitions. - No specific details pertaining to current or pending orders or order backlog were mentioned in the transcript. Therefore, no data on order book or pending orders is available from the document provided.

How does Sigachi Indust. rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisSigachi Indust.
Rev 2
See where Sigachi Indust. sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Sigachi Indust. rank in Pharmaceuticals & Biotechnology?

Compare Sigachi Indust. against every Pharmaceuticals & Biotechnology company (Q3 FY23) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Continue your research

What Sigachi Indust.'s management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • IOL Chemicals (Q1 FY27)

    Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…

  • Innova Captab (Q1 FY27)

    The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…

  • Glenmark Pharma. (Q1 FY27)

    Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…

  • Strides Pharma (Q1 FY27)

    markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…

Compare:vs Sun Pharmaceutical Industries Ltdvs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →